Founder and board member, Jamie Heywood, talks about ALS research at TEDMED
02/03/2010

When Jamie Heywood's brother was diagnosed with ALS, he devoted his life to fighting the disease as well. The Heywood brothers built an ingenious website where people share and track data on their illnesses -- and they discovered that the collective data had enormous power to comfort, explain and predict.

California Stem Cell and ALS TDI Extend Collaboration
02/02/2010

Collaboration will further evaluate novel stem cell-derived product for the treatment of fatal neurodegenerative disease by regulating genes relevant to disease progression

ALS TDI & Oxford BioMedica Collaborate to Develop Gene Therapies for ALS
01/27/2010

The ALS Therapy Development Institute and Oxford BioMedica (LSE: OXB) announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica’s preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease)

ALS TDI receives $1.6 million Grant from the DOD for Lou Gehrig’s disease Research
01/12/2010

ALS (Lou Gehrig’s disease) named Service Related Disorder Earlier Last Year

MDA Extends Funding Grant to ALS TDI into 2010
01/06/2010

Letter of Thanks from the Executive Team at ALS TDI to the ALS Community
12/30/2009

ALS TDI Presents Latest Data at International Symposium in Berlin
12/17/2009

ALS Therapy Development Institute Partners with Applied Proteomics, Inc. to Develop Protein Based Biomarkers for Amyotrophic Lateral Sclerosis
12/14/2009

20 Countries Attend International Meeting of ALS/MND Alliance
12/06/2009

A Brick and Mortar Non-Profit Biotech?
12/05/2009

This traditional approach has achieved a great many things for patients living with diseases all over the world and is one that has worked repeatedly for years, especially in providing for the care and well-being of people living with debilitating diseases in the United States and abroad. However, as has been demonstrated by the 50 rare and orphan disease group presenting at a unique meeting called Partnering for Cures

Neuroscience 2009 Recap - Wednesday October 21st
10/22/2009

Steven Perrin and Fernando Vieira Present Three Efficacy Reports to Society for Neuroscience

Neuroscience 2009 Recap - Monday October 19th
10/20/2009

Monica Wang and John Lincecum Present Data Linking Disease Progression to Immune Cells in Periphery

Winning for Winston Casino Night Raised $120,000 for ALS Research
10/14/2009

On Friday, October 2, 2009, exactly one year after Michael Winston of Mendota Heights was diagnosed with ALS at age 24, the "Winning for Winston" friends and community mobilized their effort to change the face of this disease.

5th Annual Leadership Summit Attracts Top Researchers to Cambridge this October
09/14/2009

NOW is the time to stop ALS. Come to the summit and be involved in making a future where ALS can be stopped a reality.

ALS TDI Researchers to Present at Two Upcoming Scientific Conferences
09/04/2009

Several ALS TDI researchers have been invited to present the latest work of the Institute at two important science meetings this Fall and Winter.

December 10 Research Update Video Available Now
12/17/2008

All told, there were more than 120 people, mostly ALS patients and their family members, on the live webcast and conference call.

Driving4Life Campaign reaches $7.5 Million Milestone!
12/08/2008

Report from the 16th Annual Meeting of the International Alliance
12/04/2008

Each year, the ALS/MND Alliance hosts an international symposium emphasizing emerging topics from the clinical and research fields with relevance for ALS. As has been our custom, ALS TDI sent a team of researchers to Birmingham, UK, to meet with our international colleagues, participate in the discussions and presentations and report on our progress towards therapeutic development in ALS. This short report will highlight some of the noteworthy progress that has been made in the last year.

Prize4Life Selects ALS TDI Mouse Study Standards for its $1M Treatment Prize
11/05/2008

Last month, ALS TDI was named as one of the validation centers for Prize4Life, the non-profit ALS organization that announced its $1 million ALS/MND Treatment Prize on October 21, 2008. The Avi Kremer ALS Treatment prize, named at the request of an anonymous donor for Prize4Life's founder is a rolling prize that will be awarded to the first submission that meets the specified prize criteria. If no winning submissions are received the prize will be closed on October 15, 2010.

RGK Foundation provides ALS TDI with $1Million Grant
10/28/2008

RGK Foundation grant will support the creation of potential gene therapies to treat ALS

4th Annual Leadership Summit attracts 100+ people to Boston and 160+ to Webcast. Video Available Online Now.
10/20/2008

The ALS Therapy Development Institute (ALS TDI) announced the line-up for its upcoming, annual ALS research symposium, part of the fourth annual ALS TDI Leadership Summit. The symposium will take place this October 20th at the Beacon Hill Holiday Inn in Boston, Mass.

ALS TDI to Present at the International Meeting in Birmingham, UK
10/10/2008

ALS TDI will send a team of researchers to the International meeting held Nov 3-5 not only to keep abreast of the latest developments in pre-clinical and clinical research on ALS but also to share our results working with the ALS mouse model.

ALS Patients and Researchers Unite in Boston for 4th Annual Leadership Summit
10/09/2008

Afternoon Session of Research Symposium to be Webcast
10/09/2008

ALS TDI and Clinics Partner to Accelerate Identification of Biomarkers
08/19/2008

ALS Therapy Development Institute (ALS TDI) announces the acceleration of an ALS biomarker effort using blood samples collected through an expanded network of clinical partnerships. These ongoing projects are part of the Institute's extensive effort to identify the altered expression of genes and proteins, at the onset of, and throughout the progression of the fatal neurodegenerative disease known as amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease).